EnGeneIC Partners with BioCina for Innovative Cancer Solutions
BioCina Pty Ltd., a prominent global Contract Development and Manufacturing Organization (CDMO) specializing in biologics, has forged a strategic alliance with EnGeneIC Pty Ltd. This partnership aims to transfer technology, scale up processes, and manufacture EnGeneIC's unique EnGeneIC Dream Vector, typically known as EDV.
Transforming Cancer Treatment
EnGeneIC is committed to improving cancer therapies through targeted cyto-immunotherapy. Their cutting-edge method employs Antibody-Nanocell Drug Conjugates (ANDCs) that leverage the EDV platform. This technique enables precise delivery of cytotoxic agents directly into tumor cells, thereby lowering systemic toxicity and offering new solutions for drug-resistant cancers while activating a strong anti-cancer immune response.
How the Partnership Benefits Cancer Patients
This collaboration with BioCina is geared towards developing treatments that are safer and more effective with fewer side effects, especially for patients who have run out of traditional treatment options. BioCina's expertise will be vital in preparing for the clinical and commercial manufacturing of EDVs, making this innovative therapy more accessible to those in need.
Statements from Leadership
Mark W. Womack, CEO of BioCina, shared his pride in this partnership, saying, "It's an honor for BioCina to support the advancement of EnGeneIC's groundbreaking therapies that bring hope to those dealing with treatment-resistant cancers."
Dr. Himanshu Brahmbhatt, Co-Founder and CEO of EnGeneIC, discussed the challenges of finding a reliable contract manufacturer. He expressed trust in BioCina's team, pointing out their sincere care for cancer patients and dedication to delivering high-quality therapeutics in a timely manner.
About BioCina
BioCina is well-respected for its exceptional services as a comprehensive biologics CDMO. This company excels in providing advanced services like cell line development, process optimization, analytical work, and formulation development, alongside cGMP clinical and commercial manufacturing for various modalities, including microbial, pDNA, and mRNA. Based in Adelaide, BioCina has established a strong legacy of excellence in drug substance manufacturing. They have a proven record of complying with international regulations, maintaining high-quality standards across their services.
EnGeneIC's Exciting Future
EnGeneIC, an innovative biopharmaceutical firm in the clinical stage, is at the forefront of expanding its EDV™ nanocell technology. This powerful platform allows the delivery of a variety of therapeutic agents—including drugs, siRNAs, and miRNAs—that specifically target cancer cells while reducing side effects. Their technique is particularly effective against treatment-resistant tumors and fosters a significant immune response against cancer.
Clinical Trials and Beyond
EnGeneIC is poised to enter Phase IIa clinical trials aimed at patients battling severe, low-survival cancers, including tough cases like metastatic pancreatic cancer. This upcoming phase underscores the company's commitment to offering accessible and effective solutions for those who need them most.
Frequently Asked Questions
What is the partnership between EnGeneIC and BioCina about?
The partnership is centered on technology transfer and manufacturing processes for EnGeneIC's EDV nanocells, with a goal of improving cancer treatment.
How does the EDV platform work?
The EDV platform uses antibody-targeted nanocells to directly deliver cytotoxic drugs into tumor cells, which reduces side effects and enhances treatment effectiveness.
What types of cancers is EnGeneIC targeting with its technology?
EnGeneIC's technology primarily targets drug-resistant cancers and is currently being evaluated in clinical trials for metastatic pancreatic cancer.
What are BioCina's main services?
BioCina specializes in cell line development, process and analytical development, formulation, and cGMP clinical and commercial manufacturing.
Where is BioCina located?
BioCina's main facility is situated in Australia and is recognized for its high-quality manufacturing and effective regulatory environment.
